James Shin
Stock Analyst at Deutsche Bank
(3.56)
# 2,172
Out of 4,456 analysts
83
Total ratings
56.8%
Success rate
10.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Shin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Reiterated: Buy | $1,285 | $1,208.12 | +6.36% | 20 | May 7, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $40 | $16.72 | +139.23% | 1 | Apr 24, 2026 | |
| STRO Sutro Biopharma | Reiterated: Buy | $51 → $55 | $30.52 | +80.21% | 4 | Mar 25, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $60 | $28.69 | +109.13% | 3 | Mar 9, 2026 | |
| MRK Merck & Co. | Upgraded: Buy | $111 → $150 | $128.66 | +16.59% | 9 | Feb 13, 2026 | |
| ABBV AbbVie | Maintained: Hold | $180 → $204 | $253.35 | -19.48% | 7 | Sep 15, 2025 | |
| GILD Gilead Sciences | Maintained: Buy | $120 → $135 | $127.88 | +5.57% | 5 | Aug 11, 2025 | |
| IMTX Immatics | Initiated Coverage: Buy | $10 | $9.53 | n/a | 1 | May 28, 2025 | |
| IMCR Immunocore Holdings | Initiated Coverage: Buy | $65 | $30.88 | n/a | 1 | May 27, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $45 → $53 | $57.52 | n/a | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $305 | $358.33 | n/a | 5 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $60 → $61 | $113.75 | n/a | 5 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €27.00 | $16.19 | n/a | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.61 | n/a | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $880 → $870 | $632.90 | n/a | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 → $45 | $2.08 | n/a | 2 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $24.15 | n/a | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $11 | $4.25 | n/a | 1 | Mar 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 | $0.0001 | n/a | 1 | Dec 12, 2022 |
Eli Lilly and Company
May 7, 2026
Reiterated: Buy
Price Target: $1,285
Current: $1,208.12
Upside: +6.36%
Ascentage Pharma Group International
Apr 24, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $16.72
Upside: +139.23%
Sutro Biopharma
Mar 25, 2026
Reiterated: Buy
Price Target: $51 → $55
Current: $30.52
Upside: +80.21%
Legend Biotech
Mar 9, 2026
Reiterated: Buy
Price Target: $60
Current: $28.69
Upside: +109.13%
Merck & Co.
Feb 13, 2026
Upgraded: Buy
Price Target: $111 → $150
Current: $128.66
Upside: +16.59%
AbbVie
Sep 15, 2025
Maintained: Hold
Price Target: $180 → $204
Current: $253.35
Upside: -19.48%
Gilead Sciences
Aug 11, 2025
Maintained: Buy
Price Target: $120 → $135
Current: $127.88
Upside: +5.57%
Immatics
May 28, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $9.53
Upside: n/a
Immunocore Holdings
May 27, 2025
Initiated Coverage: Buy
Price Target: $65
Current: $30.88
Upside: n/a
Bristol-Myers Squibb Company
Feb 10, 2025
Maintained: Hold
Price Target: $45 → $53
Current: $57.52
Upside: n/a
Nov 26, 2024
Maintained: Hold
Price Target: $305
Current: $358.33
Upside: n/a
Sep 19, 2024
Maintained: Hold
Price Target: $60 → $61
Current: $113.75
Upside: n/a
Aug 12, 2024
Maintained: Buy
Price Target: €27.00
Current: $16.19
Upside: n/a
Aug 9, 2024
Reiterated: Buy
Price Target: $10
Current: $1.61
Upside: n/a
Aug 1, 2024
Rated: Hold
Price Target: $880 → $870
Current: $632.90
Upside: n/a
Mar 8, 2023
Maintained: Buy
Price Target: $3 → $45
Current: $2.08
Upside: n/a
Mar 8, 2023
Maintained: Buy
Price Target: $12
Current: $24.15
Upside: n/a
Mar 5, 2023
Maintained: Hold
Price Target: $11
Current: $4.25
Upside: n/a
Dec 12, 2022
Maintained: Buy
Price Target: $7
Current: $0.0001
Upside: n/a